Supernus Pharmaceuticals (SUPN) Change in Account Payables (2014 - 2020)

Supernus Pharmaceuticals (SUPN) has 7 years of Change in Account Payables data on file, last reported at $5.7 million in Q3 2020.

• On a quarterly basis, Change in Account Payables rose 564.92% year-over-year to $5.7 million in Q3 2020; TTM through Sep 2020 was $4.7 million, a 167.8% increase from a year earlier, with the FY2019 full-year figure at $7.0 million, up 294.58% from the prior year.
• Change in Account Payables for Q3 2020 stood at $5.7 million, up from -$7.0 million in the prior quarter.
• Over the last five years, Change in Account Payables for SUPN reached as high as $7.3 million in Q4 2019 and fell as low as -$7.0 million in Q1 2020.
• Historically, Change in Account Payables has averaged $271611.1 across 5 years, with a median of -$389000.0 in 2016.
• Across the five-year window, Change in Account Payables jumped 937.63% in 2017 and slumped 1060.12% in 2018, its largest moves.
• Year by year, Change in Account Payables stood at $5.1 million in 2016, then tumbled by 86.43% to $692000.0 in 2017, then slumped by 1060.12% to -$6.6 million in 2018, then surged by 209.81% to $7.3 million in 2019, then slipped by 22.26% to $5.7 million in 2020.
• Per Business Quant data, the three most recent Change in Account Payables figures were $5.7 million in Q3 2020, -$7.0 million in Q1 2020, and $7.3 million in Q4 2019.